Summary
The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5% using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.
Similar content being viewed by others
References
Armitage P (1971) Statistical methods in medical research. Blackwell Scientific Publications, Boston 354–355
Beermann B, Hellström K, Rosén A (1971) Fate of orally administered3H-digitoxin in man with special reference to the absorption. Circulation 43: 852–861
Böttcher H, Lüllmann H, Proppe D (1973) Comparison of digoxin with some digitoxin metabolites on cat heart lung preparation. Eur J Pharmacol 22: 109–111
Dutta S, Marks BH, Stephen PM (1976) The uptake and subcellular distribution of radio-labelled metabolites of digitoxin in the guinea-pig isolated perfused heart. Br J Pharmacol 56: 437–441
Flasch H, Heinz N (1978) Correlation between inhibition of (Na+, K+) membrane — ATPase and positive inotropic activity of cardenolides in isolated papillary muscles of guinea pig. Naunyn Schmiedebergs Arch Pharmacol 304: 37–44
Graves PE, Perrier D, Marcus FI (1983) Quantitation of digitoxin and the bis- and monodigitoxosides of digitoxigenin in serum. J Chromatogr 278: 397–405
Jelliffe RW, Bechtol LD, Crabtree R (1980) The bioavailability of digitoxin. Clin Pharmacol Ther 27: 261
Lukas DS (1971) Some aspects of the distribution and disposition of digitoxin in man. Ann NY Acad Sci 179: 338–361
Perrier D, Mayersohn M, Marcus FI (1977) Clinical pharmacokinetics of digitoxin. Clin Pharmacokinetics 2: 292–311
Peters V, Funcke C, Hausamen TV, Staib W (1978) Quantitative studies on the acid hydrolysis of digitoxin. Arzneimittelforsch 28: 750–751
Rasmussen K, Jervell J, Storstein O (1971) Clinical use of a bioassay of serum digitoxin activity. Eur J Clin Pharmacol 3: 236–242
Storstein L (1976) Studies on digitalis VII: influence of nephrotic syndrome on protein binding, pharmacokinetics and renal excretion of digitoxin and cardioactive metabolites. Clin Pharmacol Ther 20: 158–166
Storstein L (1977) Studies on digitalis VIII: digitoxin metabolism on a maintenance regimen and after a single dose. Clin Pharmacol Ther 21: 125–140
Vöhringer HF, Rietbrock N (1974) Metabolism and excretion of digitoxin in man. Clin Pharmacol Ther 16: 796–806
Wirth KE, Frölich JC, Hollifield JW, Falkner FC, Sweetman BS, Oates JA (1976) Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 9: 345–354
Author information
Authors and Affiliations
Additional information
Supported by a Clinician-Scientist Award from the American Heart Association
Rights and permissions
About this article
Cite this article
MacFarland, R.T., Marcus, F.I., Fenster, P.E. et al. Pharmacokinetics and bioavailability of digitoxin by a specific assay. Eur J Clin Pharmacol 27, 85–89 (1984). https://doi.org/10.1007/BF02395212
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02395212